Correction

Correction: *BRAF*^{V600E}-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma

M. Herman Chui[1], Susanne K. Kjaer[3,4], Kirsten Frederiksen[3], Charlotte G. Hannibal[3], Tian-Li Wang[1], Russell Vang[1,2,*] and Ie-Ming Shih[1,2,*]

[1]Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

[2]Department of Obstetrics & Gynecology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

[3]Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark

[4]Gynecologic Clinic, Juliane Marie Centre, Copenhagen University Hospital, Copenhagen, Denmark

[*]These authors have contributed equally to this work

Published: *June 22, 2021*

This article has been corrected: In Table 2, the numbers in column 2, rows 2 and 3, were accidentally switched. The corrected Table 2 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2019; 10:6870–6878. https://doi.org/10.18632/oncotarget.27326

Table 2: Estimated risk of subsequent serous carcinoma by serous borderline tumor gene mutation

Gene mutation	Total number of women	Number of women with subsequent serous carcinoma	Estimated median time to progression† (years)	HR (95% CI)*	p-value
Wildtype	54	12	9.2	1.00	-
KRAS	95	22	14.4	1.00 (0.45 – 2.23)	0.99
BRAF	52	5	19.7	0.27 (0.08 – 0.93)	0.038

†time to progression derived using the Aalen-Johansen estimator.
*adjusted for age and stage (i.e. presence/absence of implants).